New biomarkers in acute kidney injury

急性肾损伤 少尿 医学 重症监护医学 肾脏疾病 无尿 肌酐 人口 内科学 肾功能 环境卫生
作者
Adam Rossiter,Ashley La,Jay L. Koyner,Lui G. Forni
出处
期刊:Critical Reviews in Clinical Laboratory Sciences [Taylor & Francis]
卷期号:61 (1): 23-44 被引量:18
标识
DOI:10.1080/10408363.2023.2242481
摘要

AbstractAcute kidney injury (AKI) is a commonly encountered clinical syndrome. Although it often complicates community acquired illness, it is more common in hospitalized patients, particularly those who are critically ill or who have undergone major surgery. Approximately 20% of hospitalized adult patients develop an AKI during their hospital care, and this rises to nearly 60% in the critically ill, depending on the population being considered. In general, AKI is more common in older adults, in those with preexisting chronic kidney disease and in those with known risk factors for AKI (including diabetes and hypertension). The development of AKI is associated with an increase in both mortality and morbidity, including the development of post-AKI chronic kidney disease. Currently, AKI is defined by a rise in serum creatinine from either a known or derived baseline value and/or oliguria or anuria. However, clinicians may fail to recognize the initial development of AKI because of a delay in the rise of serum creatinine or because of inaccurate urine output monitoring. This, in turn, delays any putative measures to treat AKI or to limit its degree. Consequently, efforts have focused on new biomarkers associated with AKI that may allow early recognition of this syndrome with the intent that this will translate into improved patient outcomes. Here we outline current biomarkers associated with AKI and explore their potential in aiding diagnosis, understanding the pathophysiology and directing therapy.Keywords: Acute kidney injuryacute kidney diseasechronic kidney diseasebiomarkers Disclosure statementJ.L.K has received consulting fees from Astute-Biomerieux, Sphingotec, Pfizer, Baxter, Mallinckrodt, Novartis, Guard Therapeutics, research funding from Astute-Biomerieux Medical, Bioporto, NxStage, Fresenius, Satellite Healthcare, and speaker fees from NxStage medical; L.G.F has received research support and lecture fees from Ortho Clinical Diagnostics, Baxter, Exthera and Biomerieux and consulting fees from La Jolla Pharmaceuticals and Paion. A.R. and A.L. declare no competing interests.Funding statementThe authors reported that there is no funding associated with the work featured in this article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyyyy完成签到,获得积分10
刚刚
奶黄包完成签到 ,获得积分10
刚刚
SYLH应助海阔天空采纳,获得10
刚刚
刚刚
机灵又蓝完成签到,获得积分10
1秒前
张土豆完成签到 ,获得积分10
1秒前
善学以致用应助小王采纳,获得10
1秒前
orang完成签到,获得积分10
2秒前
巧巧艾完成签到,获得积分10
2秒前
3秒前
邵洋完成签到,获得积分10
3秒前
sl发布了新的文献求助10
3秒前
4秒前
小迪迦奥特曼完成签到,获得积分10
4秒前
4秒前
cckk发布了新的文献求助10
5秒前
夏目由美完成签到 ,获得积分10
5秒前
Jasper应助哦哦哦采纳,获得10
6秒前
YYD完成签到,获得积分10
6秒前
超勍完成签到,获得积分10
6秒前
碧蓝碧凡发布了新的文献求助10
7秒前
Popeye应助鹤鸣采纳,获得30
7秒前
YYD发布了新的文献求助10
8秒前
yuanshl1985发布了新的文献求助10
8秒前
积极的黑猫完成签到,获得积分10
9秒前
GB完成签到 ,获得积分10
9秒前
Metx完成签到 ,获得积分10
10秒前
孤独的涔完成签到,获得积分10
11秒前
Jay完成签到,获得积分10
11秒前
12秒前
深情安青应助hf采纳,获得10
14秒前
学不懂数学应助大观天下采纳,获得10
14秒前
醉熏的水绿完成签到 ,获得积分10
14秒前
秦艺完成签到,获得积分10
15秒前
15秒前
15秒前
高高完成签到,获得积分20
16秒前
HHHHH完成签到,获得积分10
16秒前
17秒前
WANG发布了新的文献求助10
17秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029